Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study - 25/09/21

Doi : 10.1016/j.neurol.2021.06.007

J. Rigal ^a, D. Biotti ^a,^b,^c, Z. Lépine ^a, J. Ciron ^a,^b,^c,⁎
^a Department of Neurology, University Hospital of Toulouse, 31059 Toulouse cedex 9, France
^b Centre de Ressources et de Compétences Sclérose en plaques, University Hospital of Toulouse, 31059 Toulouse cedex 9, France
^c Inserm UMR1291 - CNRS UMR5051, University Toulouse 3, University Hospital of Toulouse, 31024 Toulouse cedex 3, France

^⁎Corresponding author at: Department of Neurology, University Hospital of Toulouse, place du Dr Baylac, 31059 Toulouse cedex 9, France.Department of Neurology, University Hospital of Toulouseplace du Dr BaylacToulouse cedex 931059France

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Saturday 25 September 2021
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Late-onset neutropenia (LON) after anti-CD20 therapy is a poorly described side effect in inflammatory disorders of the CNS. In this prospective study, patients treated with Rituximab or Ocrelizumab for MS, neuromyelitis optica spectrum disorders or MOG antibody-associated disease (MOGAD) were asked to perform complete blood count (CBC) every two weeks for six months, with the aim of identifying LON. Out of 152 patients, two (1,32%) had an absolute neutrophil count <1,000/mm³: one patient with MOGAD had agranulocytosis and one patient with MS had grade 3 neutropenia. Both were asymptomatic. These results confirm that LON after anti-CD20 therapy in inflammatory disorders of the CNS is not exceptional. Nevertheless, this biological complication remains too infrequent to justify close systematic CBC follow-up.

Le texte complet de cet article est disponible en PDF.

Keywords : Anti-CD20 monoclonal antibodies, Late-onset neutropenia, Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease, Neuromyelitis optica spectrum disorders (NMOSD), Multiple sclerosis